-
公开(公告)号：US20190241669A1
公开(公告)日：2019-08-08
申请号：US16384719
申请日：2019-04-15
Applicant: Pfizer Inc.
Inventor： Tracy Chia-Chien KUO , Bijan Andre BOLDAJIPOUR , Javier Fernando CHAPARRO RIGGERS , Philippe DUCHATEAU , Roman Ariel GALETTO , Alexandre JUILLERAT , Thomas Charles PERTEL , Arvind RAJPAL , Barbra Johnson SASU , Cesar Adolfo SOMMER , Julien VALTON , Thomas John VAN BLARCOM
IPC: C07K16/28 , C07K14/705 , A61K31/7076 , A61K35/17 , C12N15/63 , C07K14/725 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/7076 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2863 , C07K16/2896 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N15/63
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
公开(公告)号：US20230181634A1
公开(公告)日：2023-06-15
申请号：US16617487
申请日：2018-05-31
Applicant: Pfizer Inc.
Inventor： Barbra Johnson SASU , Danielle Elizabeth DETTLING , Cesar Adolfo SOMMER , Yik Andy YEUNG , Moustafa Marc HAMZE
IPC: A61K35/17 , C07K14/725 , C07K16/28 , C07K14/705 , C07K14/715 , A61K39/395 , A61K45/06 , A61P35/02
CPC classification number: A61K35/17 , C07K14/7051 , C07K16/2863 , C07K14/70517 , C07K14/7151 , A61K39/3955 , A61K45/06 , A61P35/02 , C07K2317/622 , A61K38/00
Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).
-
公开(公告)号：US20230059489A1
公开(公告)日：2023-02-23
申请号：US17849467
申请日：2022-06-24
Applicant: PFIZER INC.
Inventor： Danielle Elizabeth DETTLING , Yik Andy YEUNG , Kristian Todd POULSEN , Veena KRISHNAMOORTHY , Cesar Adolfo SOMMER
Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
-
公开(公告)号：US20180346601A1
公开(公告)日：2018-12-06
申请号：US15993874
申请日：2018-05-31
Applicant: PFIZER INC.
Inventor： Danielle Elizabeth DETTLING , Yik Andy YEUNG , Kristian Todd POULSEN , Veena KRISHNAMOORTHY , Cesar Adolfo SOMMER
CPC classification number: C07K16/2863 , A61K2039/505 , A61P35/02 , C07K16/2809 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/71 , C07K2317/73 , C07K2317/92
Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
-
-
-
Search Results
4
records
(took 0.015 seconds)
